These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 30273013)

  • 1. Covalent simulations of covalent/irreversible enzyme inhibition in drug discovery: a reliable technical protocol.
    Khan S; Bjij I; Olotu FA; Agoni C; Adeniji E; S Soliman ME
    Future Med Chem; 2018 Oct; 10(19):2265-2275. PubMed ID: 30273013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protocol for rational design of covalently interacting inhibitors.
    Schmidt TC; Welker A; Rieger M; Sahu PK; Sotriffer CA; Schirmeister T; Engels B
    Chemphyschem; 2014 Oct; 15(15):3226-35. PubMed ID: 25251382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Covalent Inhibition in Drug Discovery: Filling the Void in Literature.
    Bjij I; Olotu FA; Agoni C; Adeniji E; Khan S; El Rashedy A; Cherqaoui D; Soliman MES
    Curr Top Med Chem; 2018; 18(13):1135-1145. PubMed ID: 30068277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Theory and applications of covalent docking in drug discovery: merits and pitfalls.
    Kumalo HM; Bhakat S; Soliman ME
    Molecules; 2015 Jan; 20(2):1984-2000. PubMed ID: 25633330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and SAR Analysis of Covalent Inhibitors Driven by Hybrid QM/MM Simulations.
    Lodola A; Callegari D; Scalvini L; Rivara S; Mor M
    Methods Mol Biol; 2020; 2114():307-337. PubMed ID: 32016901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of novel covalent proteasome inhibitors through a combination of pharmacophore screening, covalent docking, and molecular dynamics simulations.
    Li A; Sun H; Du L; Wu X; Cao J; You Q; Li Y
    J Mol Model; 2014 Nov; 20(11):2515. PubMed ID: 25394401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinguishing the optimal binding mechanism through reversible and irreversible inhibition analysis of HSP72 protein in cancer therapy.
    Aljoundi A; El Rashedy A; Soliman MES
    Comput Biol Med; 2021 May; 132():104301. PubMed ID: 33751994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hybrid schemes based on quantum mechanics/molecular mechanics simulations goals to success, problems, and perspectives.
    Ferrer S; Ruiz-Pernía J; Martí S; Moliner V; Tuñón I; Bertrán J; Andrés J
    Adv Protein Chem Struct Biol; 2011; 85():81-142. PubMed ID: 21920322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docking covalent targets for drug discovery: stimulating the computer-aided drug design community of possible pitfalls and erroneous practices.
    Oyedele AK; Ogunlana AT; Boyenle ID; Adeyemi AO; Rita TO; Adelusi TI; Abdul-Hammed M; Elegbeleye OE; Odunitan TT
    Mol Divers; 2023 Aug; 27(4):1879-1903. PubMed ID: 36057867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promiscuity and selectivity in covalent enzyme inhibition: a systematic study of electrophilic fragments.
    Jöst C; Nitsche C; Scholz T; Roux L; Klein CD
    J Med Chem; 2014 Sep; 57(18):7590-9. PubMed ID: 25148591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medicinal Chemistry Projects Requiring Imaginative Structure-Based Drug Design Methods.
    Moitessier N; Pottel J; Therrien E; Englebienne P; Liu Z; Tomberg A; Corbeil CR
    Acc Chem Res; 2016 Sep; 49(9):1646-57. PubMed ID: 27529781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic Studies on the Protocol and Criteria for Selecting a Covalent Docking Tool.
    Wen C; Yan X; Gu Q; Du J; Wu D; Lu Y; Zhou H; Xu J
    Molecules; 2019 Jun; 24(11):. PubMed ID: 31185706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversible versus irreversible inhibition modes of ERK2: a comparative analysis for ERK2 protein kinase in cancer therapy.
    Khan S; Bjij I; Betz RM; Soliman ME
    Future Med Chem; 2018 May; 10(9):1003-1015. PubMed ID: 29629569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virtual Screening of Novel Glucosamine-6-Phosphate Synthase Inhibitors.
    Lather A; Sharma S; Khatkar A
    Comb Chem High Throughput Screen; 2018; 21(3):182-193. PubMed ID: 29600755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of Covalent Ligands via Noncovalent Docking by Dissecting Covalent Docking Based on a "Steric-Clashes Alleviating Receptor (SCAR)" Strategy.
    Ai Y; Yu L; Tan X; Chai X; Liu S
    J Chem Inf Model; 2016 Aug; 56(8):1563-75. PubMed ID: 27411028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ensemble-based docking using biased molecular dynamics.
    Campbell AJ; Lamb ML; Joseph-McCarthy D
    J Chem Inf Model; 2014 Jul; 54(7):2127-38. PubMed ID: 24881672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combining docking and molecular dynamic simulations in drug design.
    Alonso H; Bliznyuk AA; Gready JE
    Med Res Rev; 2006 Sep; 26(5):531-68. PubMed ID: 16758486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Covalent inhibitors design and discovery.
    De Cesco S; Kurian J; Dufresne C; Mittermaier AK; Moitessier N
    Eur J Med Chem; 2017 Sep; 138():96-114. PubMed ID: 28651155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Dynamics as a Tool for Virtual Ligand Screening.
    Menchon G; Maveyraud L; Czaplicki G
    Methods Mol Biol; 2018; 1762():145-178. PubMed ID: 29594772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toward Atomistic Modeling of Irreversible Covalent Inhibitor Binding Kinetics.
    Yu HS; Gao C; Lupyan D; Wu Y; Kimura T; Wu C; Jacobson L; Harder E; Abel R; Wang L
    J Chem Inf Model; 2019 Sep; 59(9):3955-3967. PubMed ID: 31425654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.